Published in Front Pharmacol on July 05, 2012
Smartphone Training for Attention Regulation for IBS | NCT05083091
Extra-intestinal and long term consequences of Giardia duodenalis infections. World J Gastroenterol (2013) 1.17
Irritable bowel syndrome: a clinical review. World J Gastroenterol (2014) 1.10
Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers. Gastroenterol Res Pract (2015) 0.91
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol (2013) 0.91
Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y) (2014) 0.91
Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol (2013) 0.88
Constipation and herbal medicine. Front Pharmacol (2015) 0.87
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology (2013) 0.86
What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol (2013) 0.85
Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer. Front Pharmacol (2016) 0.84
Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.84
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels. Br J Pharmacol (2014) 0.81
Molecular and functional diversity of GABA-A receptors in the enteric nervous system of the mouse colon. J Neurosci (2014) 0.81
Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. Eur J Pharmacol (2014) 0.81
Early-life stress origins of gastrointestinal disease: animal models, intestinal pathophysiology, and translational implications. Am J Physiol Gastrointest Liver Physiol (2015) 0.81
Cognitive behavioral approach to understanding irritable bowel syndrome. World J Gastroenterol (2014) 0.81
'As above, so below' examining the interplay between emotion and the immune system. Immunology (2014) 0.79
Personality traits and emotional patterns in irritable bowel syndrome. World J Gastroenterol (2016) 0.79
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol (2016) 0.78
Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.78
Decreased neuroplasticity may play a role in irritable bowel syndrome: implication from the comorbidity of depression and irritable bowel syndrome. J Neurogastroenterol Motil (2015) 0.77
Cognitive Functions and Depression in Patients with Irritable Bowel Syndrome. Gastroenterol Res Pract (2015) 0.77
The application of functional magnetic resonance imaging in an infant rat model of irritable bowel syndrome. Gastroenterol Res Pract (2014) 0.76
Novel insights which may translate into treatments for irritable bowel syndrome. Front Pharmacol (2013) 0.76
Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. World J Gastroenterol (2016) 0.75
Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. J Neurogastroenterol Motil (2017) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
The need for a new medical model: a challenge for biomedicine. Science (1977) 29.54
Pattern recognition receptors and inflammation. Cell (2010) 21.05
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev (2007) 11.15
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol (2004) 5.21
Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol (2003) 4.70
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology (2007) 4.58
The role of psychological and biological factors in postinfective gut dysfunction. Gut (1999) 4.54
Regional dissociations within the hippocampus--memory and anxiety. Neurosci Biobehav Rev (2004) 4.44
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology (2004) 4.04
A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med (2008) 3.91
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut (2008) 3.81
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut (2004) 3.55
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev (2005) 3.32
Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology (2000) 3.32
Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut (2000) 3.26
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A (2001) 3.23
Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis (2006) 3.10
The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol (1999) 3.10
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A (2001) 2.87
Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med (2001) 2.33
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut (2006) 2.33
Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology (2003) 2.32
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology (2006) 2.28
Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol (2010) 2.23
Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology (2006) 2.19
Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol (2010) 2.02
Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology (2002) 2.02
Psychosocial aspects of the functional gastrointestinal disorders. Gut (1999) 1.99
Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil (2007) 1.98
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry (1999) 1.97
The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology (2009) 1.94
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol (2005) 1.93
Variations in maternal care in infancy regulate the development of stress reactivity. Biol Psychiatry (2000) 1.91
What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol (2000) 1.91
Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology (2010) 1.90
Presidential address: Gastrointestinal illness and the biopsychosocial model. Psychosom Med (1998) 1.88
Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology (2006) 1.85
Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology (2006) 1.83
Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther (2010) 1.81
Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology (2010) 1.75
Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology (2000) 1.72
Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci (2008) 1.70
The 5-HT3 receptor--the relationship between structure and function. Neuropharmacology (2008) 1.70
Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther (2012) 1.64
Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med (2001) 1.64
Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut (2004) 1.58
Review article: irritable bowel syndrome. Aliment Pharmacol Ther (1997) 1.51
The neurology of the immune system: neural reflexes regulate immunity. Neuron (2009) 1.46
Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J Physiol (2004) 1.45
CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol (2004) 1.44
Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage (2008) 1.43
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil (2008) 1.41
Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphé differentially affect serotonin release in the nucleus accumbens. Eur J Pharmacol (2007) 1.39
Central and medial amygdaloid brain-derived neurotrophic factor signaling plays a critical role in alcohol-drinking and anxiety-like behaviors. J Neurosci (2006) 1.39
The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut (2002) 1.39
Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology (2010) 1.37
Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut (2005) 1.37
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol (1998) 1.35
Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut (2000) 1.34
Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology (2009) 1.33
Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology (1998) 1.33
Irritable bowel syndrome: towards biomarker identification. Trends Mol Med (2009) 1.29
Stereotaxic localization of corticosterone to the amygdala enhances hypothalamo-pituitary-adrenal responses to behavioral stress. Brain Res (2003) 1.29
White matter abnormalities in irritable bowel syndrome and relation to individual factors. Brain Res (2011) 1.28
Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport (1997) 1.27
Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disord (2008) 1.27
Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev (2011) 1.25
Stress and visceral pain: from animal models to clinical therapies. Exp Neurol (2011) 1.25
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol (2009) 1.24
Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol Motil (1996) 1.24
Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol (2007) 1.24
Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain (2000) 1.23
Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2006) 1.22
Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology (2007) 1.22
Abnormal forebrain activity in functional bowel disorder patients with chronic pain. Neurology (2005) 1.19
Infection, inflammation, and the irritable bowel syndrome. Dig Liver Dis (2009) 1.19
Cortical thinning in IBS: implications for homeostatic, attention, and pain processing. Neurology (2007) 1.17
Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl) (2010) 1.17
Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol (1998) 1.17
Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.16
Peptides that fine-tune the serotonin system. Neuropeptides (2005) 1.16
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol (2010) 1.16
Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology (2009) 1.16
CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des (2006) 1.15
Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in rats. Brain Res (2001) 1.15
Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol (2006) 1.14
Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther (2010) 1.14
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil (2009) 1.14
Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet (2002) 1.13
Review article: the psychoneuroimmunology of irritable bowel syndrome--an exploration of interactions between psychological, neurological and immunological observations. Aliment Pharmacol Ther (2008) 1.13
Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity. Nat Commun (2013) 2.08
Microscopic colitis -- a common cause of diarrhoea in older adults. Age Ageing (2010) 1.24
Eosinophilic colitis: epidemiology, clinical features, and current management. Therap Adv Gastroenterol (2011) 1.15
Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis (2011) 0.96
Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2011) 0.92
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol (2013) 0.91
Cytokines and irritable bowel syndrome: where do we stand? Cytokine (2011) 0.89
Eosinophilic colitis: an update on pathophysiology and treatment. Br Med Bull (2011) 0.84
Juvenile polyposis of the stomach--a novel cause of hypergastrinemia. Nat Rev Gastroenterol Hepatol (2010) 0.84
Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? Can J Gastroenterol Hepatol (2014) 0.82
The association between celiac disease and eosinophilic esophagitis in children and adults. BMC Gastroenterol (2013) 0.82
The novel endomorphin degradation blockers Tyr-Pro-DClPhe-Phe-NH (EMDB-1) and Tyr-Pro-Ala-NH (EMDB-2) prolong endomorphin-2 action in rat ileum in vitro. Chem Biol Drug Des (2010) 0.79
New neostigmine-based behavioral mouse model of abdominal pain. Pharmacol Rep (2012) 0.79
Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract. Regul Pept (2010) 0.78